Tag: Ladiratuzumab vedotin
Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered...
During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020, Seagen (previously known as Seattle...
Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development...
Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize ladiratuzumab vedotin an investigational antibody-drug...
AACR 2018: Highlighting Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology
This year, the American Association for Cancer Research (AACR) will host their annual meeting April 14 - 18, 2018 in the McCormick Place North/South...
Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...
Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...
Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...
Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...
